RxDoctor Payments DataLook up a doctor →

Alison Berndt

Family · Bel Air, MDNPI 1568834588

Payments from drug & device makers

$11,053in general payments, 2019–2025

Across 454 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Inspire Medical Systems, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$876
  • Jazz Pharmaceuticals Inc.$614
  • Grifols USA, LLC$610
  • plus $5K from 33 others

What the payments were for

  • Travel & lodging$5795%
  • Food & beverage$10,21792%
  • Education$2572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,053 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$114,190
Medicare patients
601
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter357$369,502
Breo ElliptaFluticasone/Vilanterol152$103,351
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr100$81,319
Breztri AerosphereBudesonide/Glycopyr/Formoterol90$78,084
Spiriva RespimatTiotropium Bromide82$59,191
Arnuity ElliptaFluticasone Furoate78$22,483
Incruse ElliptaUmeclidinium Bromide28$17,430
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$15,789
Advair HfaFluticasone Propion/Salmeterol18$13,564
Combivent RespimatIpratropium/Albuterol Sulfate14$11,633
Albuterol Sulfate HfaAlbuterol Sulfate215$9,639
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$8,001
SymbicortBudesonide/Formoterol Fumarate22$7,823
DuleraMometasone/Formoterol21$6,748
Roflumilast46$3,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$2,029$594,085715 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$452$86,613116 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,314$85,907112 claims
MerckDulera$17$6,74821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →